Ethinyl Estradiol and Norgestimate

Brand names: Norgestimate And Ethinyl Estradiol · Active ingredient: Norgestimate, Ethinyl Estradiol

In short: Sprintec ®(norgestimate and ethinyl estradiol tablets) is indicated for use by females of reproductive potential to prevent pregnancy .

Forms & strengthsSprintec (norgestimate and ethinyl estradiol tablets USP) is available in blister cards. Each blister card contains 28 tablets in the following order: 21 blue, round, flat-faced, beveled-edge, unscored tablet debossed with stylized bon one side and 987on the …
LabelPD-Rx Pharmaceuticals, Inc.
Label updatedNov 05, 2026

What is Ethinyl Estradiol and Norgestimate used for?

Sprintec

®(norgestimate and ethinyl estradiol tablets) is indicated for use by females of reproductive potential to prevent pregnancy

.

⚠ Boxed warning (FDA's strongest warning)

Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive (COC) use. This risk increases with age, particularly in women over 35 years of age, and with the number of cigarettes smoked. For this reason, COCs are contraindicated in women who are over 35 years of age and smoke

.

Ethinyl Estradiol and Norgestimate dosage

Take one tablet by mouth at the same time each day with or without food. Table 1 provides the recommended dosage and administration instructions for Sprintec.

Table 1: Instructions for Administration of Sprintec

Starting COCs in women not currently using hormonal contraception (Day 1 Start or Sunday Start)

Important:Consider the possibility of ovulation and conception prior to initiation of this product.

Tablet Color:

Sprintec active tablets are blue (Day 1 to Day 21).

Sprintec has white inactive tablets (Day 22 to Day 28). | Day 1 Start:

Take first active tablet without regard to meals on the first day of menses.

Take subsequent active tablets once daily at the same time each day for a total of 21 days.

Take one

whiteinactive tablet daily for 7 days and at the same time of day that active tablets were taken.

Begin each subsequent pack on the same day of the week as the first cycle pack (i.e., on the day after taking the last inactive tablet)

Sunday Start:

Take first active tablet without regard to meals on the first Sunday after the onset of menses.

Due to the potential risk of becoming pregnant, use additional non-hormonal contraception (such as condoms and spermicide) for the first seven days of the patient’s first cycle pack of Sprintec.

Take subsequent active tablets once daily at the same time each day for a total of 21 days.

Take one

whiteinactive tablet daily for the following 7 days and at the same time of day that active tablets were taken.

Begin each subsequent pack on the same day of the week as the first cycle pack (i.e., on the Sunday after taking the last inactive tablet) and additional non-hormonal contraceptive is not needed.

Switching to Sprintec from another oral contraceptive | Start on the same day that a new pack of the previous oral contraceptive would have started.

Switching from another contraceptive method to Sprintec | Start Sprintec:

Transdermal patch | On the day when next application would have been scheduled

Vaginal ring | On the day when next insertion would have been scheduled

Injection | On the day when next injection would have been scheduled

Intrauterine contraceptive | On the day of removal

If the IUD is not removed on first day of the patient’s menstrual cycle, additional non-hormonal contraceptive (such as condoms and spermicide) is needed for the first seven days of the first cycle pack.

Implant | On the day of removal

Complete instructions to facilitate patient counseling on proper tablet usage are located in the FDA-Approved Patient Labeling.

Starting Sprintec after Abortion or Miscarriage

First-trimester

After a first-trimester abortion or miscarriage, Sprintec may be started immediately. An additional method of contraception is not needed if Sprintec is started immediately. …

How to take Ethinyl Estradiol and Norgestimate — instructions & advice from the label

See FDA-approved patient labeling (Patient Information and Instructions for Use).

Counsel patients about the following information:

Cigarette smoking increases the risk of serious cardiovascular events from COC use, and that women who are over 35 years old and smoke should not use COCs

.

Increased risk of VTE compared to non-users of COCs is greatest after initially starting a COC or restarting (following a 4-week or greater pill-free interval) the same or a different COC

.

Sprintec does not protect against HIV infection (AIDS) and other sexually transmitted infections.

Sprintec is not to be used during pregnancy; if pregnancy occurs during use of Sprintec instruct the patient to stop further use

.

Take one tablet daily by mouth at the same time every day. Instruct patients what to do in the event tablets are missed

.

Use a back-up or alternative method of contraception when enzyme inducers are used with Sprintec

.

COCs may reduce breast milk production; this is less likely to occur if breastfeeding is well established

. …

Warnings & precautions

Do not take this medicine if: Sprintec is contraindicated in females who are known to have or develop the following conditions:

A high risk of arterial or venous thrombotic diseases. Examples include women who are known to:

Smoke, if over age 35

Have deep vein thrombosis or pulmonary embolism, now or in the past

Have inherited or acquired hypercoagulopathies

Have cerebrovascular disease

Have coronary artery disease

Have thrombogenic valvular or thrombogenic rhythm diseases of the heart (for example, subacute bacterial endocarditis with valvular disease, or atrial fibrillation)

Have uncontrolled hypertension

Have diabetes mellitus with vascular disease

Have headaches with focal neurological symptoms or migraine headaches with aura

Women over age 35 with any migraine headaches

Liver tumors, benign or malignant, or liver disease

Undiagnosed abnormal uterine bleeding

Current diagnosis of, or history of, breast cancer, which may be hormone-sensitive

Use of Hepatitis C drug combinations containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir, due to the potential for ALT elevations

Stop Sprintec if an arterial thrombotic event or venous thromboembolic (VTE) event occurs.

Stop Sprintec if there is unexplained loss of vision, proptosis, diplopia, papilledema, or retinal vascular lesions. Evaluate for retinal vein thrombosis immediately

.

If feasible, stop Sprintec at least 4 weeks before and through 2 weeks after major surgery or other surgeries known to have an elevated risk of VTE as well as during and following prolonged immobilization.

Start Sprintec no earlier than 4 weeks after delivery, in women who are not breastfeeding. The risk of postpartum VTE decreases after the third postpartum week, whereas the risk of ovulation increases after the third postpartum week.

The use of COCs increases the risk of VTE. …

Ethinyl Estradiol and Norgestimate side effects

The following serious adverse reactions with the use of COCs are discussed elsewhere in labeling:

Serious cardiovascular events and stroke

Vascular events

Liver disease

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

The safety of norgestimate and ethinyl estradiol was evaluated in 1,647 healthy women of child-bearing potential who participated in 3 clinical trials and received at least 1 dose of norgestimate and ethinyl estradiol for contraception. Two trials were randomized active-controlled trials and 1 was an uncontrolled open-label trial. In all 3 trials, subjects were followed for up to 24 cycles.

Common Adverse Reactions (≥ 2% of subjects): The most common adverse reactions reported by at least 2% of the 1,647 women were the following in order of decreasing incidence: headache/migraine (32.9%), abdominal/gastrointestinal pain (7.8%), vaginal infection (8.4%), genital discharge (6.8%), breast issues (including breast pain, discharge, and enlargement) (6.3%), mood disorders (including depression and mood altered) (5.0%), flatulence (3.2%), nervousness (2.9%), and rash (2.6%).

Adverse Reactions Leading to Study Discontinuation: Over the three trials, between 11 to 21% of subjects discontinued the trial due to an adverse reaction. …

Drug interactions

Consult the labeling of concurrently used drugs to obtain further information about interactions with hormonal contraceptives or the potential for enzyme alterations.

No drug-drug interaction studies were conducted with Sprintec.

Substances decreasing the plasma concentrations of COCs

Drugs or herbal products that induce certain enzymes, including cytochrome P450 3A4 (CYP3A4), may decrease the plasma concentrations of COCs and potentially diminish the effectiveness of COCs or increase breakthrough bleeding. Some drugs or herbal products that may decrease the effectiveness of hormonal contraceptives include phenytoin, barbiturates, carbamazepine, bosentan, felbamate, griseofulvin, oxcarbazepine, rifampicin, topiramate, rifabutin, rufinamide, aprepitant, and products containing St. John’s wort. Interactions between hormonal contraceptives and other drugs may lead to breakthrough bleeding and/or contraceptive failure. Counsel women to use an alternative method of contraception or a back-up method when enzyme inducers are used with COCs, and to continue back-up contraception for 28 days after discontinuing the enzyme inducer to ensure contraceptive reliability. …

About this medicine

Sprintec

®(norgestimate and ethinyl estradiol tablets USP) is a combination oral contraceptive containing the progestational compound norgestimate, USP and the estrogenic compound ethinyl estradiol, USP.

Each blue tablet contains 0.250 mg of the progestational compound norgestimate (18, 19-Dinor-17-pregn-4-en-20-yn-3-one,17-(acetyloxy)-13-ethyl-, oxime, (17α)-(+)-) and 0.035 mg of the estrogenic compound, ethinyl estradiol (19-nor-17α-pregna, 1,3,5(10)-trien-20-yne-3, 17-diol), and the inactive ingredients include anhydrous lactose, FD&C blue no. 2 aluminum lake, lactose monohydrate, magnesium stearate, and pregelatinized corn starch.

Each white tablet contains only inert ingredients as follows: anhydrous lactose, hypromellose, magnesium stearate, and microcrystalline cellulose.

The structural formula is as follows:

C

23H

31NO

3M.W. 369.50

C

20H

24O

2M.W. 296.40

How it works: Oral Contraception COCs lower the risk of becoming pregnant primarily by suppressing ovulation. No specific pharmacodynamic studies were conducted with Sprintec. …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 00dd9b78-dd90-414b-b241-7619aa9d1ed2. Read the full official label on DailyMed.